Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 30, 2024
Reporting Period: Single event date (September 30, 2024)
Business Context: The Company is an emerging growth company focused on developing immunotherapies. This filing discloses a regulatory milestone regarding its lead candidate, CLD-101.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Regulatory Milestone: On September 30, 2024, the Company announced that the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for a clinical trial of CLD-101 in high-grade glioma.
Collaboration: The trial is being conducted in collaboration with Northwestern University.
Guidance, Outlook, and Risks
Outlook: The FDA clearance enables the initiation of the clinical trial for CLD-101 in high-grade glioma, advancing the Company's development pipeline.
Risks and Contingencies: The filing includes standard disclaimers stating that the information is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act. No specific financial risks or contingencies are detailed in this document.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific trial design details and enrollment timelines.
- Review the Company's most recent 10-Q or 10-K filing for current cash runway and liquidity status, as this 8-K contains no financial data.
- Monitor subsequent filings for updates on patient enrollment and data readouts from the Northwestern University trial.
- Confirm the status of the Company's other pipeline assets and any ongoing regulatory interactions.